CN102058757B - 一种治疗心血管疾病的中药组合物及其制备方法 - Google Patents
一种治疗心血管疾病的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN102058757B CN102058757B CN2010105586779A CN201010558677A CN102058757B CN 102058757 B CN102058757 B CN 102058757B CN 2010105586779 A CN2010105586779 A CN 2010105586779A CN 201010558677 A CN201010558677 A CN 201010558677A CN 102058757 B CN102058757 B CN 102058757B
- Authority
- CN
- China
- Prior art keywords
- bulbus allii
- allii macrostemonis
- ethanol
- adds
- filter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 60
- 238000000034 method Methods 0.000 claims abstract description 25
- 239000006187 pill Substances 0.000 claims abstract description 23
- 239000007901 soft capsule Substances 0.000 claims abstract description 13
- 206010002383 Angina Pectoris Diseases 0.000 claims abstract description 11
- 239000002775 capsule Substances 0.000 claims abstract description 8
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 8
- 239000003826 tablet Substances 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 225
- 230000006837 decompression Effects 0.000 claims description 42
- 238000004064 recycling Methods 0.000 claims description 42
- 238000010992 reflux Methods 0.000 claims description 42
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 37
- 241000180649 Panax notoginseng Species 0.000 claims description 37
- 238000001035 drying Methods 0.000 claims description 31
- 239000012141 concentrate Substances 0.000 claims description 26
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 22
- 238000002156 mixing Methods 0.000 claims description 22
- 239000006228 supernatant Substances 0.000 claims description 21
- 239000002671 adjuvant Substances 0.000 claims description 9
- 201000005577 familial hyperlipidemia Diseases 0.000 claims description 4
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 3
- 239000006196 drop Substances 0.000 claims description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 2
- 241000304531 Allium macrostemon Species 0.000 abstract 1
- 241000212322 Levisticum officinale Species 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000002481 ethanol extraction Methods 0.000 abstract 1
- 239000001645 levisticum officinale Substances 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 238000003809 water extraction Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 22
- 241000700159 Rattus Species 0.000 description 17
- 239000000843 powder Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 239000013641 positive control Substances 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 9
- 108010023302 HDL Cholesterol Proteins 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000009413 insulation Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 241000700157 Rattus norvegicus Species 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 4
- 206010053567 Coagulopathies Diseases 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000008118 PEG 6000 Substances 0.000 description 4
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 4
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 4
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 230000035602 clotting Effects 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- 206010002660 Anoxia Diseases 0.000 description 3
- 241000976983 Anoxia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000007953 anoxia Effects 0.000 description 3
- 239000007766 cera flava Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- IROWCYIEJAOFOW-UHFFFAOYSA-N DL-Isoprenaline hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(O)C(O)=C1 IROWCYIEJAOFOW-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 239000008899 fufang danshen Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229940018448 isoproterenol hydrochloride Drugs 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 229940083037 simethicone Drugs 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 206010052895 Coronary artery insufficiency Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- HWGBHCRJGXAGEU-UHFFFAOYSA-N Methylthiouracil Chemical compound CC1=CC(=O)NC(=S)N1 HWGBHCRJGXAGEU-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical class C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940127021 low-dose drug Drugs 0.000 description 1
- 229960002545 methylthiouracil Drugs 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- -1 nitrous acid ester Chemical class 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000009982 suxiao jiuxinwan Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
组别 | 动物数(只) | 剂量(g生药/kg) | 凝血时间(s) |
本发明高剂量组 | 10 | 7 | 90.00±14.31* |
本发明低剂量组 | 10 | 3.5 | 70.00±22.14 |
阳性对照组 | 10 | 5 | 80.00±20.22* |
空白对照组 | 10 | - | 60.00±27.31 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010105586779A CN102058757B (zh) | 2010-11-25 | 2010-11-25 | 一种治疗心血管疾病的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010105586779A CN102058757B (zh) | 2010-11-25 | 2010-11-25 | 一种治疗心血管疾病的中药组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102058757A CN102058757A (zh) | 2011-05-18 |
CN102058757B true CN102058757B (zh) | 2012-07-04 |
Family
ID=43994382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010105586779A Expired - Fee Related CN102058757B (zh) | 2010-11-25 | 2010-11-25 | 一种治疗心血管疾病的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102058757B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103623189B (zh) * | 2012-08-28 | 2019-06-14 | 吴宗贵 | 一种消退和逆转动脉粥样硬化斑块的复方中药制剂及其制备方法 |
CN103566146B (zh) * | 2013-10-10 | 2015-09-30 | 广西中医药大学 | 一种治疗缺血性中风的药物及其制备方法 |
CN104491194A (zh) * | 2014-12-07 | 2015-04-08 | 肖玉翠 | 用于治疗心肺瘀阻型风湿性心脏病的药物及其制备方法 |
CN104940846A (zh) * | 2015-07-21 | 2015-09-30 | 相宏杰 | 一种用于治疗动脉粥样硬化的中药组合物 |
CN105535446A (zh) * | 2016-02-26 | 2016-05-04 | 武步旭 | 一种治疗心肌梗塞的中药 |
CN107349318B (zh) * | 2017-07-25 | 2020-11-20 | 盐城师范学院 | 一种降血脂瓜蒌皮复方及其制备方法 |
CN107714857A (zh) * | 2017-12-01 | 2018-02-23 | 王章琳 | 一种治疗心脑血管病的中药组合物及其制备方法 |
CN116509955A (zh) * | 2023-06-19 | 2023-08-01 | 中国中医科学院西苑医院 | 一种用于冠心病心绞痛的中药组合物、外用贴和方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101569708A (zh) * | 2008-04-29 | 2009-11-04 | 孟凡香 | 一种治疗缺血性心脏病的药物及其制备方法 |
-
2010
- 2010-11-25 CN CN2010105586779A patent/CN102058757B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101569708A (zh) * | 2008-04-29 | 2009-11-04 | 孟凡香 | 一种治疗缺血性心脏病的药物及其制备方法 |
Non-Patent Citations (5)
Title |
---|
刘元.冠心病中医治疗十法.《医药世界》.2005,(第08期),68. * |
刘哯等.治疗冠心病心绞痛的中医常用方药.《中国临床医生》.2000,(第10期),16-19. * |
王师菡等.基于信息熵法提取名老中医治疗冠心病心绞痛的药对.《中华中医药学刊》.2008,(第10期),2150-2152. * |
陈世虎等.中成药治疗冠心病的现状.《中成药》.2005,(第09期),附13-附15. * |
黄素芳等.治疗冠心病中药使用频率的研究分析.《中药新药与临床药理》.2009,(第04期),395-396. * |
Also Published As
Publication number | Publication date |
---|---|
CN102058757A (zh) | 2011-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102058757B (zh) | 一种治疗心血管疾病的中药组合物及其制备方法 | |
CN102166335A (zh) | 生姜与荜拨组合物、其制备方法及其在制备癌症放、化疗中减毒增效药物中的用途 | |
CN102166338A (zh) | 草豆蔻与生姜组合物、其制备方法及其在制备癌症放、化疗中减毒增效药物中的用途 | |
CN104225217A (zh) | 一种治疗冠心病的中药制剂及其制备方法 | |
CN101850032A (zh) | 一种具有抗肿瘤作用的中药组合物及其制备方法和应用 | |
CN102579560A (zh) | 当归黄芪合剂水提物的制备方法及干预肺纤维化的应用 | |
CN101757391B (zh) | 一种治疗心血管疾病的药物组合物及其制备方法和用途 | |
CN102133385A (zh) | 生姜与白胡椒组合物、其制备方法及其在制备癌症放、化疗中减毒增效药物中的用途 | |
CN102526667B (zh) | 用于减少癌症化疗引起的呕吐并对化疗增效的枇杷叶与生姜组合物及其制备方法 | |
CN101849950A (zh) | 救必应酸在制备调血脂的药物中的应用 | |
CN115531463B (zh) | 一种治疗高脂血症的中药 | |
CN103211858A (zh) | 一种四君子滴丸制剂 | |
CN102423384B (zh) | 一种治疗肺癌的中药制剂及其制备方法 | |
CN102552847B (zh) | 用于减少癌症化疗引起的呕吐并对化疗增效的生姜与旋覆花组合物及其制备方法 | |
CN101167771A (zh) | 长春花及其提取物在制备抗艾滋病药物中的用途 | |
CN101940318B (zh) | 一种具有镇咳、抗炎和降血脂功能的软胶囊及制备方法 | |
CN104547026A (zh) | 一种丹参叶三七提取物的制备方法及其应用 | |
CN104547027B (zh) | 一种丹参叶三七叶提取物的制备方法及其应用 | |
CN102133383B (zh) | 生姜与佛手组合物、其制备方法及其在制备癌症放、化疗中减毒增效药物中的用途 | |
CN102120000A (zh) | 抗柯萨奇b病毒中药制剂有效部位的组合物及其制备方法 | |
CN102688296B (zh) | 一种具有降血脂作用的中药组合物及其制备方法和应用 | |
CN100551404C (zh) | 利水消肿药物组合物的制备与检测方法和用途 | |
CN101380356A (zh) | 藏药独一味总黄酮提取物及其提取方法和用途 | |
CN101129997A (zh) | 郁金解表口服液 | |
CN105288107A (zh) | 复方沙棘清咽组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160206 Address after: 210033, room 402, building F7, Jiangsu life science and Technology Innovation Park, No. 9 weft Lu, Qixia District, Jiangsu, Nanjing Patentee after: NANJING TIANYUAN PEPTIDE PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Address before: 250355 College of science and technology, Changqing District, Shandong City, Ji'nan Province, Shandong University of Traditional Chinese Medicine Patentee before: Dai Long |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180207 Address after: 100086 Beijing city Haidian District Qingyun aromatic garden Ting Building 9, Tsing Wun contemporary building room 1706B3 Patentee after: BEIJING KAIRUI INNOVATION PHARMACEUTICAL TECHNOLOGY CO.,LTD. Address before: 210033, room 402, building F7, Jiangsu life science and Technology Innovation Park, No. 9 weft Lu, Qixia District, Jiangsu, Nanjing Patentee before: NANJING TIANYUAN PEPTIDE PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20181204 Address after: 100102 floor 3, floor 106, Li Ze Chung garden, Chaoyang District, Beijing, 313A, 315A Patentee after: Beijing bio Pharmaceutical Technology Co.,Ltd. Address before: 100086 Room 1706B3, Qingyun Contemporary Building, Building 9, Manting Fangyuan District, Haidian District, Beijing Patentee before: BEIJING KAIRUI INNOVATION PHARMACEUTICAL TECHNOLOGY CO.,LTD. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190910 Address after: 100080 Room 1706B3, Qingyun Contemporary Building, Building 9, Manting Fangyuan District, Haidian District, Beijing Patentee after: BEIJING KAIRUI INNOVATION PHARMACEUTICAL TECHNOLOGY CO.,LTD. Address before: Room 3, 313A and 315A of Building 106, Lize Zhongyuan, Chaoyang District, Beijing, 100102 Patentee before: Beijing bio Pharmaceutical Technology Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120704 Termination date: 20211125 |